Comparison of Procedural and 1-Year Clinical Results of Transcatheter Aortic Valve Implantation Using Prostheses with Different Design of Support Frame

Li, Fēi; Wang, Xu; Wang, Yuetang; Li, Xuan; Xu, Donghui; Zhao, Shihua; Wang, Chunsheng; Guo, Yingqiang; Wu, Yongjian; Wang, Wei

doi:10.1536/ihj.20-398

Cited by 6 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By the end of 2019, more than 4000 cases of TAVR had been completed in about 200 hospitals in more than 20 provinces and cities in China, of which more than 2600 cases had been completed in 2019. 34 4 In this study, there were 404 cases (19.31%) of patients with BAV in 10 articles, 13,16,17,20,21,23,26,27,30,32 the proportion of Chinese population with BAV is higher than that of western countries, the BAV stenosis have anatomic particularities such as elliptic annulus, high calcification, and asymmetry of the valve, unequal valves, enlarged ascending aorta, and/or transversal heart. 35 Additionally, the effect of TAVR in patients with BAV is not inferior to that of the tricuspid aortic valve (TAV) [36][37][38][39] in China.…”

Section: Postprocedural Complicationsmentioning

confidence: 77%

See 1 more Smart Citation

The current practice of transcatheter aortic valve replacement in China

Xie

Yao

2022

Journal of Cardiac Surgery

View full text Add to dashboard Cite

Objective: The purpose of this study is to summarize the current practice and experience of transcatheter aortic valve replacement in China.Methods: The relevant articles were identified through computerized searches of the CNKI, WANFANG, VIP, and PubMed databases through February 1, 2022, using the search terms: "transcatheter aortic valve replacement," "transcatheter aortic valve implantation," "China."Results: The database searches identified 22 articles, 2092 patients, 57.65% were male, with a mean age of 74.2 ± 6.0 years, 71.51% of patients were classified by New York Heart Association as class Ⅲ/Ⅳ, Society of Thoracic Surgeons score 8.4 ± 4.1, mean left ventricular ejection fraction 52.8 ± 14.2%, mean transvalvular aortic pressure gradient 59.9 ± 18.9 mmHg. The overall procedural success rate was 97.85%, and 2.15% of patients were converted to sternotomy, mainly due to transcatheter aortic bioprosthesis dislocation. The most common vascular access approach was transfemoral (1071 patients, 51.20%). General anesthesia (48.90%) was the commonly used anesthesia technique. The incidence of postprocedural complications was as follows: permanent pacemaker implantation (10.47%), bleeding events (8.60%), mild paravalvular leakage (17.73%), moderate and severe paravalvular leakage (4.16%), vascular complications (3.30%), stroke (1.43%), respectively. The overall periprocedural period and postprocedural 30-day mortality was 2.72%.Conclusions: Among patients undergoing transcatheter aortic valve replacement in China, device implantation success was achieved in 97.85% of cases. The most common vascular access approach was transfemoral. General anesthesia was the most commonly used anesthetic technique. Paravalvular leakage (458 patients, 21.89%) was the most common complication.

show abstract

Section: Postprocedural Complicationsmentioning

confidence: 77%

“…Among the literature included in the current study, 15 articles 12,13,15,[17][18][19][20]23,[26][27][28][29][30]32,33 had clear inclusion and exclusion criteria, shown in Table 2, including the China expert consensus. 34…”

Section: Inclusion and Exclusion Criteria Of Tavr Patientsmentioning

confidence: 99%

The current practice of transcatheter aortic valve replacement in China

Xie

Yao

2022

Journal of Cardiac Surgery

View full text Add to dashboard Cite

show abstract

“…In September 2012, the Fuwai Hospital was the first to successfully perform TAVR using the domestic Venus-A valve (Venus Medtech Co., Hangzhou, China) and initiated the clinical registry of Venus-A valve, marking the arrival of the domestic TAVR device era. An early single-center clinical study in China has shown that the Venus-A valve had similar 2-year survival outcomes to the CoreValve in patients unable to undergo surgery and surgically high-risk patients (11.1% vs. 7.4%, P = 0.64) [29] and similar 1-year survival outcomes to the Sapien valve and J-Valve ( P = 0.850), [30] providing early evidence to support the application of the Venus-A valve.…”

Section: Transcatheter Aortic Valve Replacement (Tavr)mentioning

confidence: 96%

Current Status and Challenges of Valvular Heart Disease Interventional Therapy

Zhang

Xiong

Feng

2022

Cardiology Discovery

View full text Add to dashboard Cite

Valvular heart disease (VHD) is common in the global population, occupying an heavy disease burden among aging population. Currently, it is the booming era of transcatheter VHD treatment, even with superiority than traditional open heart surgery in some clinical outcomes. We collected data sources mainly derived from published articles and conference presentations, including randomized controlled trials, first-in-man studies, clinical registries, and other single-or multi-center and prospective or retrospective clinical studies. This review summarized the relevant devices and researches of transcatheter aortic valve replacement, transcatheter mitral valve repair and replacement, transcatheter tricuspid valve repair and replacement, and transcatheter pulmonary valve replacement. Moreover, possible challenges of interventional therapy for various VHD in the future were discussed as well.

show abstract

“…Although the TAVI-related one-year mortality in Western Europe has dropped considerably, a one-year mortality rate as high as 19.9% was reported in 2015 [1]. In-hospital mortality after TAVI has been significantly reduced in 2014 (4.2%) compared with 2008 (10.4%) [2], but 30-day mortality still is 7%, and one-year all-cause mortality may range between 11% [3] and 22.7% for patients with low-flow low-gradient aortic stenosis and even reach 24.1% for patients with moderate/severe impaired left ventricular function [4]. Moreover, the rate of acute (up to 30 days) TAVI complications is 23.1% [5].…”

Section: Introductionmentioning

confidence: 99%

A Novel Method to Predict Mortality and Length of Stay after Transfemoral Transcatheter Aortic Valve Implantation

et al. 2021

View full text Add to dashboard Cite

Background and Objectives: We tested if a novel combination of predictors could improve the accuracy of outcome prediction after transfemoral transcatheter aortic valve implantation (TAVI). Materials and Methods: This prospective study recruited 169 participants (49% female; median age 81 years). The primary endpoint was midterm mortality; secondary endpoints were acute Valve Academic Research Consortium (VARC)-3 complication rate and post-TAVI in-hospital length of stay (LoS). EuroSCORE II (ESII), comorbidities (e.g., coronary artery disease), eGFR (estimated glomerular filtration rate; based on cystatin C), hemoglobin, creatinine, N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) levels and patient-reported outcome measures (PROMs, namely EuroQol-5-Dimension-5-Levels, EQ5D5L; Kansas City Cardiomyopathy Questionnaire, KCCQ; clinical frailty scale, CFS) at baseline were tested as predictors. Regression (uni- and multi-variate Cox; linear; binary logistic) and receiver operating characteristic (ROC)-curve analysis were applied. Results: Within a median follow-up of 439 (318–585) days, 12 participants died (7.1%). Independent predictors of mortality using multivariate Cox regression were baseline eGFR (p = 0.001) and KCCQ (p = 0.037). Based on these predictors, a Linear Prediction Score (LPS1) was calculated. The LPS1-area under the curve (AUC)-value (0.761) was significantly higher than the ESII-AUC value (0.597; p = 0.035). Independent predictors for LoS > 6 days (the median LoS) were eGFR (p = 0.028), NTproBNP (p = 0.034), and EQ5D5L values (p = 0.002); a respective calculated LPS2 provided an AUC value of 0.677 (p < 0.001). Eighty participants (47.3%) experienced complications. Male sex predicted complications only in the univariate analysis. Conclusions: The combination of KCCQ and eGFR can better predict midterm mortality than ES II alone. Combining eGFR, NTproBNP, and EQ5D5L can reliably predict LoS after TAVI. This novel method improves personalized TAVI risk stratification and hence may help reduce post-TAVI risk.

show abstract

Comparison of Procedural and 1-Year Clinical Results of Transcatheter Aortic Valve Implantation Using Prostheses with Different Design of Support Frame

Cited by 6 publications

References 32 publications

The current practice of transcatheter aortic valve replacement in China

The current practice of transcatheter aortic valve replacement in China

Current Status and Challenges of Valvular Heart Disease Interventional Therapy

A Novel Method to Predict Mortality and Length of Stay after Transfemoral Transcatheter Aortic Valve Implantation

Contact Info

Product

Resources

About